Clinical Trials Browser

Phase 1/2 × Anatomic Stage IV Breast Cancer AJCC v8 × Magnetic Resonance Spectroscopy × Clear all

NCT06026657 2025-07-08

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

Phase 1/2 Recruiting

Anatomic Stage IV Breast Cancer AJCC v8